临床试验/NCT04831320

NCT04831320进行中（未招募）2 期

Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor: A Single-Arm, Phase 2 Trial

Washington University School of Medicine1 个研究点分布在 1 个国家目标入组 46 人开始时间: 2021年9月28日最近更新: 2026年7月6日

适应症

干预措施

试验速览

阶段: 2 期
状态: 进行中（未招募）
发起方: Washington University School of Medicine
入组人数: 46
试验地点: 1
主要终点: Objective response rate (ORR) as assessed by RECIST 1.1

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The primary hypothesis is that the objective response rate (ORR) with nab-paclitaxel and nivolumab will be significantly higher than the historical control (ORR 30%).

The KEY secondary hypothesis is that the median PFS with nab-paclitaxel and nivolumab will be significantly longer than the historical control (median PFS 3.6 months).

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Histologically or cytologically confirmed recurrent or metastatic HNSCC of the oral cavity, larynx, hypopharynx, oropharynx, or p16 positive neck node with unknown primary (but clinically thought to be oropharynx).
•Known p16 status (positive or negative) if oropharynx or unknown primary of the neck.
•Measurable disease per RECIST. Measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 10 mm with CT scan, as ≥ 20 mm by chest x-ray, or ≥ 10 mm with calipers by clinical exam.
•Progression of disease, as assessed by RECIST, that occurred on a PD-1 or PD-L1 inhibitor (given alone or with other therapy) to treat recurrent or metastatic disease. Progression of disease that occurred on a PD-1 or PD-L1 inhibitor given as a component of a curative-intent regimen is excluded.
•PD-L1 CPS by IHC (22C3 antibody) on tumor tissue is strongly encouraged to be available or performed, although the test result is not required to enroll onto the trial. Patients with tumor PD-L1 TPS (but not CPS) available are also eligible; but, PD-L1 CPS should be performed in these cases. Fresh tumor tissue (obtained after progression on prior PD-1 or PD-L1 inhibitor given for recurrent or metastatic disease) is strongly preferred, but archived tumor tissue from recurrence or initial diagnosis is also acceptable.
•At least 18 years of age.
•ECOG performance status < 1
•Normal bone marrow and organ function as defined below:
•Hemoglobin > 9 g/L
•Absolute neutrophil count ≥ 1,500/mcl
•Platelets ≥ 100,000/mcl (transfusion independent, defined as not receiving platelet transfusions within 7 days prior to laboratory sample)
•Total bilirubin ≤ 1.5 mg/dL
•AST(SGOT)/ALT(SGPT) ≤ 2.5 x IULN (in cases of bone mets or liver mets, AST/ALT < 5 x IULN)
•Serum creatinine <1.5 x IULN or creatinine clearance > 50 mL/min by Cockcroft-Gault
•The effects of nivolumab and nab-paclitaxel on the developing human fetus are unknown. For this reason and because monoclonal antibodies and antimicrotubule agents are known to be teratogenic, women of childbearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry, for the duration of study participation, and for 6 months after the last dose of study treatment. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
•Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable) before the performance of any protocol-related procedures.

排除标准

•A history of other malignancy with the exception of malignancies for which all treatment was completed at least 1 year before registration and the patient has no evidence of disease.
•Has known active CNS metastases. Subjects with previously treated brain metastases may participate provided they are stable (without any evidence of progression by imaging 4 weeks prior to the first dose of study treatment and any neurologic symptoms have stabilized), have no evidence of new or enlarging brain metastases, and are on stable or tapering doses of steroids for at least 14 days prior to first dose of study treatment.
•A history of serious allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in the study (Allergic reaction to cetuximab is allowed as there are other standard of care options for the investigator's choice arm).
•Receiving systemic corticosteroid therapy (in doses exceeding 10 mg daily of prednisone equivalent) within 7 days prior to the first dose of treatment. A history of severe autoimmune disorder requiring high-dose corticosteroid treatment due to prior PD-1 inhibitor is an exclusion criterion.
•Greater than Grade 2 pre-existing peripheral neuropathy (per CTCAE).
•Uncontrolled serious intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
•Pregnant and/or breastfeeding. Women of childbearing potential must have a negative serum pregnancy test within 24 hours prior to the start of study treatment.
•Prior organ or allogeneic stem cell transplant.
•Has an active autoimmune disease (i.e. rheumatoid arthritis, lupus, Sjogren's syndrome) that has required IV or subcutaneous systemic treatment in the past 6 months (excluding Rituxan). Replacement therapy (i.e. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
•Prisoners, or subjects who are compulsory detained.
•Prior taxane (including paclitaxel or docetaxel) given to treat recurrent or metastatic disease.
•Prior taxane (including paclitaxel or docetaxel) given as a component of a curatively intended multimodality therapy IF the latter was completed within 6 months of subsequent development of recurrent or metastatic disease.

研究组 & 干预措施

nab-Paclitaxel + Nivolumab

Experimental

nab-Paclitaxel 125 mg/m^2 intravenous (IV) on days 1, 8 & 15 of each 28-day cycle.
Nivolumab 480 mg IV Day 1 of each 28-day cycle.

干预措施: nab-paclitaxel (Drug)

nab-Paclitaxel + Nivolumab

Experimental

nab-Paclitaxel 125 mg/m^2 intravenous (IV) on days 1, 8 & 15 of each 28-day cycle.
Nivolumab 480 mg IV Day 1 of each 28-day cycle.

干预措施: Nivolumab (Drug)

结局指标

主要结局

Objective response rate (ORR) as assessed by RECIST 1.1

时间窗: Through completion of treatment (estimated to be 4 months)

* ORR: Proportion of patients who achieve a complete or partial response to treatment * Complete Response (CR): Disappearance of all target lesions. Disappearance of all non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. * Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

次要结局

Number of dose reductions of nab-paclitaxel(Through completion of treatment (estimated to be 4 months))
Incidence of immune-related adverse events(Through 100 days after completion of treatment (estimated to be 7.5 months))
Number of dose delays of nivolumab(Through completion of treatment (estimated to be 4 months))
Number of dose delays of nab-paclitaxel(Through completion of treatment (estimated to be 4 months))
Number of dose interruptions of nivolumab(Through completion of treatment (estimated to be 4 months))
Duration of response (DOR)(Through completion of treatment (estimated to be 4 months))
Incidence of adverse events(Through 100 days after completion of treatment (estimated to be 7.5 months))
Progression-free survival (PFS)(Through completion of follow-up (estimated to be 13 months))
Number of dose reductions of nivolumab(Through completion of treatment (estimated to be 4 months))
Number of dose interruptions of nab-paclitaxel(Through completion of treatment (estimated to be 4 months))
Overall survival (OS)(Through completion of follow-up (estimated to be 13 months))

研究者

发起方

Washington University School of Medicine

申办方类型

Other

责任方

Sponsor

研究点 (1)

Loading locations...

相似试验

招募中

2 期

Phase II study of nab-paclitaxel plus ramucirumab in combination with nivolumab in unresectable advanced or recurrent gastric cancer after progression to first-line therapy including fluoropyrimidine, platinum, and anti-PD-1/PD-L1 antibody.nresectable advanced or recurrent gastric cancer

JPRN-jRCT2031220448Shoji Hirokazu45

招募中

2 期

Phase II study of nab-paclitaxel in combination with carboplatin in patients with refractory small-cell lung cancerRefractory small-cell lung cancer

JPRN-UMIN000015565Dokkyo Medical University22

撤回

1 期

Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC AdenocarcinomaNSCLC, RecurrentAdenocarcinoma of Lung

NCT03361319Royal Marsden NHS Foundation Trust

已完成

2 期

Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)Triple-negative Metastatic Breast CancerHER2- Negative Breast CancerRecurrent Breast CancerCancer of the BreastProgesterone Receptor- Negative Breast CancerStage IV Breast CancerTriple-negative Breast CancerEstrogen Receptor- Negative Breast CancerBreast TumorBreast CancerMetastatic Breast Cancer

NCT01881230Celgene191

已完成

2 期

NCT03342911Sidney Kimmel Cancer Center at Thomas Jefferson University34